Cyclic Citrullinated Peptide Antibody IgG Market 2026: 8.2% CAGR Growth Driven by 94% RA Diagnostic Specificity & Novel Assay Innovations
Title: Cyclic Citrullinated Peptide Antibody IgG Market 2026: 8.2% CAGR Growth Driven by 94% RA Diagnostic Specificity & Novel Assay Innovations Abstract: The cyclic citrullinated peptide (CCP) antibody IgG market is projected to grow at an 8.2% CAGR through 2026, driven by its 94% specificity for rheumatoid arthritis (RA) diagnosis. Novel assay innovations enhance sensitivity and automation, outperforming traditional RF tests. Key brands (e.g., Roche, Abbott, Euroimmun) compete on precision and throughput. Market trends favor high-purity synthetic peptides with validated certificates (CE/FDA). Product selection prioritizes lot-to-lot consistency, cold-chain logistics, and third-party quality certifications. This growth reflects expanding autoimmune diagnostics and peptide-based therapeutic monitoring.